Erlotinib in Treating Patients With Recurrent or Progressive Glioblastoma Multiforme
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Erlotinib may stop the growth of cancer cells by blocking the enzymes necessary
for cancer cell growth.
PURPOSE: Phase II trial to study the effectiveness of erlotinib in treating patients who have
recurrent or progressive glioblastoma multiforme.